



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/395096/2019

European Medicines Agency decision P/0272/2019

of 14 August 2019

on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix) (EMEA-000696-PIP02-10-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0272/2019

of 14 August 2019

on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix) (EMA-000696-PIP02-10-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/213/2011 issued on 2 September 2011, the decision P/0058/2012 issued on 26 March 2012, the decision P/0284/2012 issued on 23 November 2012, the decision P/0197/2013 issued on 2 September 2013 and the decision P/0015/2015 issued on 30 January 2015,

Having regard to the application submitted by BIAL - Portela & Ca, SA on 21 March 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix), oral suspension, tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to BIAL - Portela & Ca, SA, À Av. da Siderurgia Nacional, 4745-457 - S. Mamede do Coronado, Portugal.

EMA/PDCO/216955/2019
Amsterdam, 28 June 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000696-PIP02-10-M06

Scope of the application

Active substance(s):

Eslicarbazepine (acetate)

Invented name:

Zebinix

Condition(s):

Treatment of epilepsy with partial onset seizures

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Oral suspension

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

BIAL - Portela & Ca, SA

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, BIAL - Portela & Ca, SA submitted to the European Medicines Agency on 21 March 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/213/2011 issued on 2 September 2011, the decision P/0058/2012 issued on 26 March 2012, the decision P/0284/2012 issued on 23 November 2012, the decision P/0197/2013 issued on 2 September 2013 and the decision P/0015/2015 issued on 30 January 2015.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 30 April 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition: treatment of epilepsy with partial onset seizures

The waiver applies to:

- all subsets of the paediatric population from birth to less than 1 month years of age;
- for oral suspension, tablet; oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition: treatment of epilepsy with partial onset seizures

2.1.1. Indication(s) targeted by the PIP

Treatment of epilepsy with partial onset seizures with eslicarbazepine acetate (ESL) as adjunctive therapy

Treatment of epilepsy with partial onset seizures with eslicarbazepine acetate (ESL) as monotherapy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 month to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Oral suspension

Tablet

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1 Development of standardised dosing device(s) for the age-appropriate oral suspension
Non-clinical	2	Study 2 Toxicity and toxicokinetic study of 28 days repeat doses of eslicarbazepine acetate (ESL) in juvenile dogs Study 3 10-month oral (gavage) toxicity study of ESL in juvenile dogs with a 2-month recovery period

Clinical	7	Study 4 Open-label, multiple-dose study to evaluate pharmacokinetics, safety and tolerability of eslicarbazepine acetate (ESL) for partial-onset epilepsy in paediatric patients from 2 years to less than 18 years Study 5 Double blind parallel-group, randomised placebo-controlled, multicentre, 2 part study in paediatric patients with partial-onset seizures aged from 6 years to less than 16 years to evaluate efficacy and safety, including effect on cognitive function of eslicarbazepine acetate (ESL) as adjunctive therapy with an open-label extension (48 weeks) Study 6 Double-blind, randomised, placebo-controlled, parallel-group, multi-centre trial to evaluate efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in children aged 2 years to less than 18 years with a one year open-label extension phase Study 7 Open-label, 2 dose level trial to evaluate pharmacokinetics, safety and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy in infants with refractory epilepsy with partial-onset seizures aged from 1 month to less than 2 years Study 8 Double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial to evaluate efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in children aged from 7 months to less than 24 months with a one year open-label extension phase Study 9 Double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial to evaluate safety and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in children aged from 1 month to less than 7 months with a one year open-label extension phase Study 10 Double-blind, randomised, parallel-group, multicenter study to evaluate efficacy and safety of eslicarbazepine acetate (ESL) as monotherapy for children aged from 4 years to less than 18 years with newly diagnosed partial-onset seizures Study 11 Open-label, multicentre study to evaluate tolerability and safety of eslicarbazepine acetate (ESL) as monotherapy for young children 1 month to 4 years with newly diagnosed partial-onset seizures Study 12 Double blind study in paediatric epileptic subjects aged from 5 years to less than 8 years to compare the subject preference for eslicarbazepine acetate (ESL) oral suspension formulation with alternative flavours
----------	---	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2020
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of epilepsy with partial onset seizures

Authorised indication(s):

- monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;
- adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

Authorised pharmaceutical form(s):

Oral suspension

Tablet

Authorised route(s) of administration:

Oral use